Treatment with anti-CGRP monoclonal antibodies in patients with idiopathic intracranial hypertension: a pilot study

被引：0
|
作者：
Krajnc, N. [1 ]
Macher, S. [1 ]
Marik, W. [2 ]
Michl, M. [3 ]
Novak, K. [4 ]
Woeber, C. [1 ]
Pemp, B. [3 ]
Bsteh, G. [1 ]
机构：
[1] Med Univ Vienna, Dept Neurol, Vienna, Austria
[2] Med Univ Vienna, Dept Neuroradiol, Vienna, Austria
[3] Med Univ Vienna, Dept Ophthalmol, Vienna, Austria
[4] Med Univ Vienna, Dept Neurosurg, Vienna, Austria
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-253
引用
收藏
页码：485 / 486
页数：2
相关论文
共 50 条
  • [1] Treatment with anti-CGRP mAbs in patients with idiopathic intracranial hypertension: a pilot study
    Krajnc, N.
    Macher, S.
    Marik, W.
    Michl, M.
    Novak, K.
    Wober, C.
    Pemp, B.
    Bsteh, G.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [2] Effectiveness of anti-CGRP monoclonal antibodies for persistent headaches in patients with idiopathic intracranial hypertension
    Frerichs, L.
    Nandy, K.
    Friedman, D., I
    HEADACHE, 2022, 62 : 106 - 107
  • [3] Safety concerns of treatment with anti-CGRP monoclonal antibodies in patients with migraine
    van der Arend, Britt W. H.
    van Veelen, Nancy
    de Ruijter, Joelle E. T.
    Olsen, Michael H.
    van den Brink, Antoinette Maassen
    Terwindt, Gisela M.
    CEPHALALGIA, 2023, 43 (1supp) : 233 - 233
  • [4] Anti-CGRP and Anti-CGRP Receptor Monoclonal Antibodies for Migraine Prophylaxis: Retrospective Observational Study on 209 Patients
    Schweiger, Vittorio
    Bellamoli, Paola
    Taus, Francesco
    Gottin, Leonardo
    Martini, Alvise
    Nizzero, Marta
    Bonora, Eleonora
    Del Balzo, Giovanna
    Donadello, Katia
    Secchettin, Erica
    Finco, Gabriele
    De Santis, Daniele
    Polati, Enrico
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (04)
  • [5] RETRACTION: Effectiveness of anti-CGRP monoclonal antibodies for persistent headaches in patients with idiopathic intracranial hypertension (Retraction of Vol 62, art no 106, 2022)
    Frerichs, L.
    Nandy, K.
    Friedman, D., I
    HEADACHE, 2024, 64 (06): : 713 - 713
  • [6] Treatment patterns of patients with migraine eligible for anti-CGRP pathway monoclonal antibodies
    Khodavirdi, Ani C.
    Multani, Jasjit K.
    Oh, Sam S.
    Vuvu, Fiston
    Bensink, Mark E.
    Stockl, Karen M.
    Hawkins, Kevin
    Chiang, Chia-Chun
    Green, A. Laine
    Tepper, Stewart J.
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [7] Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Migraine
    Hennessy, Elise
    Salim, Amira
    Biswas, Sudipa
    Suneja, Aarushi
    Mays, Maryann
    Ahmed, Zubair
    Mata, Ignacio
    NEUROLOGY, 2023, 100 (17)
  • [8] Safety considerations in the treatment with anti-CGRP(R) monoclonal antibodies in patients with migraine
    Van der Arend, Britt W. H.
    Van Veelen, Nancy
    De Ruijter, Joelle E. T.
    Olsen, Michael H.
    MaassenVanDenBrink, Antoinette
    Terwindt, Gisela M.
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [9] Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study
    Simona Guerzoni
    Flavia Lo Castro
    Daria Brovia
    Carlo Baraldi
    Luca Pani
    Neurological Sciences, 2024, 45 : 1661 - 1668
  • [10] Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study
    Guerzoni, Simona
    Castro, Flavia Lo
    Brovia, Daria
    Baraldi, Carlo
    Pani, Luca
    NEUROLOGICAL SCIENCES, 2024, 45 (04) : 1661 - 1668
12345